

F. Seltzer

March 10, 1976

Dr. Lennart Klang
Kungshögsvägen 6
S-260 14 Glumslöv
Sweden

Dear Dr. Klang,

Your letter of 23 December was sent to my former University, and just forwarded to me - I regret the delay in replying.

Following our work on cyclazocine and naloxone, as referred to in 1971, the U.S. Government actively supported the development of a new antagonist, naltrexone. This drug has had extensive clinical trials, and now seems superior to earlier antagonists. Clinical trials are still under research auspices, and the drug is not yet marketed.

Most laboratories which tested the antagonists found their use too difficult. When patients have the choice between methadone or naltrexone, they surely prefer methadone. I believe that in N.Y., only my former co-worker, Dr. Richard Resnick is actively using naltrexone. He reports good clinical results.

I do not believe that naltrexone will be very successful, especially when it continues to compete with methadone.

Thank you for your inquiry.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry